Charneux Julie, Lorin Johanna, Vitry Fabien, Antonicelli Frank, Reguiai Ziad, Barbe Coralie, Tabary Thierry, Grange Florent, Bernard Philippe
Service de Dermatologie, Hôpital Robert Debré, Reims, France.
Arch Dermatol. 2011 Mar;147(3):286-91. doi: 10.1001/archdermatol.2011.23.
To investigate the diagnostic value of commercially available BP230 and BP180-NC16a enzyme-linked immunosorbent assays (ELISAs) in routine practice in patients with bullous pemphigoid (BP).
Single-center retrospective study.
French academic dermatology department.
The study population comprised 138 patients, who were admitted from January 1998 through December 2008.
Sera samples were analyzed by ELISA; clinical and immunopathological data were recorded from the patients' medical charts.
BP230 and BP180-NC16a ELISA scores were evaluated with respect to clinical characteristics (number of blisters, mucosal involvement, localized or generalized disease, and outcome) and routine indirect immunofluorescence (IF).
Of the 138 study patients, 81 (59%) had a positive BP230 ELISA result and 119 (86%) had a positive BP180 ELISA result. There was no relationship between a positive ELISA BP230 result and the disease extent at diagnosis or the presence of mucosal involvement. Serum anti-basement membrane zone autoantibodies (indirect IF) were more frequently detected when the BP230 ELISA result was positive (P < .001). The median anti-basement membrane autoantibody titer as detected by indirect IF was higher in patients with a positive BP230 result (P < .001). The BP180 ELISA result was associated with disease extent at diagnosis as estimated by both the percentage of patients with extensive BP (P = .01) and the mean number of blisters (P = .03) but was not associated with mucosal involvement.
The currently available BP230 ELISA is a reliable although less-sensitive test than BP180 ELISA in BP, and its diagnostic added value compared with BP180 ELISA alone is approximately 5%. Our results support the predominant contribution of the BP230-specific autoantibodies to anti-basement membrane zone antibody titer as detected by indirect IF.
探讨市售BP230和BP180-NC16a酶联免疫吸附测定(ELISA)在大疱性类天疱疮(BP)患者常规诊疗中的诊断价值。
单中心回顾性研究。
法国学术性皮肤科。
研究人群包括1998年1月至2008年12月期间收治的138例患者。
采用ELISA分析血清样本;从患者病历中记录临床和免疫病理数据。
根据临床特征(水疱数量、黏膜受累情况、局限性或全身性疾病及转归)和常规间接免疫荧光法(IF)评估BP230和BP180-NC16a ELISA评分。
138例研究患者中,81例(59%)BP230 ELISA结果为阳性,119例(86%)BP180 ELISA结果为阳性。BP230 ELISA阳性结果与诊断时疾病范围或黏膜受累情况之间无相关性。当BP230 ELISA结果为阳性时,血清抗基底膜带自身抗体(间接IF)更常被检测到(P <.001)。BP230结果为阳性的患者中,间接IF检测到的抗基底膜自身抗体滴度中位数更高(P <.001)。BP180 ELISA结果与诊断时疾病范围相关,根据广泛型BP患者百分比(P =.01)和水疱平均数(P =.03)评估,但与黏膜受累情况无关。
目前可用的BP230 ELISA是一种可靠的检测方法,尽管在BP中比BP180 ELISA敏感性低,与单独使用BP180 ELISA相比,其诊断附加值约为5%。我们的结果支持BP230特异性自身抗体对间接IF检测到的抗基底膜带抗体滴度起主要作用。